Genentech Reports Results of Xofluza (baloxavir marboxil) in P-III MINISTONE-2 Study for Influenza in Children

 Genentech Reports Results of Xofluza (baloxavir marboxil) in P-III MINISTONE-2 Study for Influenza in Children

Genentech Reports Results of Xofluza (baloxavir marboxil) in P-III MINISTONE-2 Study for Influenza in Children

Shots:

  • The P-III MINISTONE-2 (NCT03629184) study involves assessing of Xofluza vs Oseltamivir in children with an influenza infection aged b\w 1 to ≤12yrs. confirmed by rapid influenza diagnostic test/ influenza symptoms
  • The P-III MINISTONE-2 study resulted in meeting its 1EPs demonstrating reduction in duration of flu symptoms including fever and is well tolerated in children with flu
  • Xofluza is an oral therapy approved in the US & Japan in treating influenza in children, being evaluated in P-III MINISTONE-1 study for flu in children < 1yr. with its expected FDA’s sNDA approval on Nov 04, 2019

Click here to read full press release/ article | Ref: Genentech | Image: Commercial Cafe

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post